Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed Hamed Salem

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Clinical Pharmacokinetics|March 21, 2015
A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patientsChay Ngee Lim, Ahmed Hamed Salem
Clinical and Translational Science|May 23, 2024
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitorAhmed Hamed Salem, Rajeev M Menon
Clinical Pharmacokinetics|December 6, 2013
Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patientsAhmed Hamed Salem, Denise Koenig, Dawn Carlson
Anti-Cancer Drugs|June 1, 2017
Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemiaAhmed Hamed Salem, Martin Dunbar, Suresh K Agarwal
European Journal of Clinical Pharmacology|January 6, 2018
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokineticsKevin J Freise, Beibei Hu, Ahmed Hamed Salem
Journal of Cancer|October 22, 2019
A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall SurvivalAbhinav Kurumaddali, Ahmed Hamed Salem, Suresh K Agarwal
Journal of Clinical Pharmacology|January 5, 2017
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelKevin J Freise, Mohamad Shebley, Ahmed Hamed Salem
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2019
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?Aksana K Jones, Ahmed Hamed Salem, Kevin J Freise
Clinical and Translational Science|July 4, 2019
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response AnalysisNimita Dave, Sathej Gopalakrishnan, Sven Mensing, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2013
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected childrenAhmed Hamed Salem, Courtney V Fletcher, Richard C Brundage
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Clinical Pharmacokinetics|March 21, 2015
A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patientsChay Ngee Lim, Ahmed Hamed Salem
Clinical and Translational Science|May 23, 2024
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitorAhmed Hamed Salem, Rajeev M Menon
Clinical Pharmacokinetics|December 6, 2013
Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patientsAhmed Hamed Salem, Denise Koenig, Dawn Carlson
Anti-Cancer Drugs|June 1, 2017
Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemiaAhmed Hamed Salem, Martin Dunbar, Suresh K Agarwal
European Journal of Clinical Pharmacology|January 6, 2018
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokineticsKevin J Freise, Beibei Hu, Ahmed Hamed Salem
Journal of Cancer|October 22, 2019
A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall SurvivalAbhinav Kurumaddali, Ahmed Hamed Salem, Suresh K Agarwal
Journal of Clinical Pharmacology|January 5, 2017
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelKevin J Freise, Mohamad Shebley, Ahmed Hamed Salem
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2019
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?Aksana K Jones, Ahmed Hamed Salem, Kevin J Freise
Clinical and Translational Science|July 4, 2019
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response AnalysisNimita Dave, Sathej Gopalakrishnan, Sven Mensing, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2013
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected childrenAhmed Hamed Salem, Courtney V Fletcher, Richard C Brundage
Pageof 9